🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections annually. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices at this time.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which uses two antibiotics. The research enrolled over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have expressed positive views. The availability of a single-dose, oral treatment like this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.